Risk of Chronic Diseases in Young Adults Born Preterm: Relationship With Inflammation and Oxidative Stress Biomarkers.

Overview

The purpose of the HAPI project is to study the overall health of preterm infants once they reach adulthood. The investigators would like to compare the health of adults born preterm with that of adults born full-term. They would also like to find the early signs, or biomarkers, of chronic diseases such as high blood pressure, diabetes, osteoporosis, and chronic lung diseases. Such biomarkers would allow for early diagnosis and prevention. Furthermore, the investigators would like to understand why some people born preterm are more likely to develop chronic disease. They believe that inflammation and oxidative stress may play a part. Oxidative stress is present when the body is not able to defend itself against oxygen-derived products that can damage our cells. To carry out this study, the investigators will examine 6 aspects of the health: (1) heart and circulation, (2) kidneys, (3) lungs, (4) metabolism – sugars and fats in the blood, (5) bones, and (6) eyes.

Study Type

  • Study Type: Observational [Patient Registry]
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: March 29, 2017

Detailed Description

The participants, from both groups will spend a whole day at St. Justine's hospital. Upon arrival after an overnight fast, vital signs and anthropometric measures are taken. Then blood and urine are obtained as well and a pregnancy test is performed for women. After inserting a intravenous catheter, around 55 mL of blood is taken and sent to the biochemistry department and to our laboratory. A oral glucose tolerance test is also performed with blood sampling over 2hours. Then a renal and carotid ultrasounds, as well as a osteodensitometry test (bone mineral density and body muscle/fat composition) are done. Ophtalmology exam is realized by ophtalmologist, including visual acuity, contrast and fundus photograph, then the participants are provided with a standardized light lunch. A thorough cardiac ultrasound, as well as assessment of major arteries (aorta, carotid, brachial) structure and function are performed. Pulmonary function tests are done before a fitness test for VO2 max, and repeated with bronchodilatator after the fitness test. Prior to leaving, participants are given a ambulatory blood pressure monitor for them to carry for 24 consecutive hours over the following 2 days. Prior to the study day, participants are sent questionnaires to be filled in advance by themselves and by each of their parent. During the study day, other questionnaires regarding their lifestyles and medical condition are also filled. Overall, information is obtained about: (1) Socio-economic status: Occupation, education level and income of participant and parents. (2) Family history: Parental health (including maternal pregnancies) and familial (1st and 2nd degree) premature history of cardiovascular diseases (CVD), type-2 diabetes, chronic pulmonary or renal diseases. (3) Personal medical history: Current medication use (including anti-inflammatory medications), medical history, current symptoms, and growth parameters from birth to present (according to medical records and child health care booklet), age at menarche. (4) Health-related behaviors: (a) regular physical activities (Minnesota and Huet validated questionnaires) (b) Smoking and alcohol consumption. (c) Diet assessed through the validated and self-administered 73-item Food Frequency Questionnaire (FFQ). (d) SF-36 Health Survey. In addition to the study protocol, the subjects are invited to contribute extra biosamples to our blood (3 ml) and urine (1 ml) biobank.

Interventions

  • Other: preterm birth
    • The study compares young adult subjects born premature (< 29 weeks) versus term (-> 37 weeks)

Arms, Groups and Cohorts

  • Extremely preterm (EPT)
    • All adults born at gestational age (GA) <29 wks at CHU Sainte-Justine (CHUSJ), the Royal Victoria Hospital (RVH), and the Jewish General Hospital (JGH), Montreal, in 1987-97. Inclusion criteria: (a) Birth at GA<29 wks, (b) age 18-29 years at the time of assessment (age of peak human physiological function). Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion. In case of twins (or +), if both fulfil inclusion criteria, only one will selected (random) to participate to the study.
  • Term or controls
    • Same-sex friends identified by EPT subject who have accepted to be contacted. Inclusion criteria: (a) Birth at GA ≥37 wks, (b) born in Quebec, to account for health care access during pregnancy and throughout infancy/childhood, (c) birth date within 2 years of index case, (d) age 18-29 years at the time of assessment, (e) same self-reported race as preterm participant. Exclusion criteria: (a) currently pregnant due to X-ray related risks, (b) severe neurosensory deficit preventing test completion.

Clinical Trial Outcome Measures

Primary Measures

  • Markers of inflammation
    • Time Frame: 1 hour
    • Blood samples for measurements of biomarkers of inflammation are collected in the morning the day of the visit. Monocyte chemoattractant-1 (pg/mL), Interleukine-6 (pg/mL), tumor necrosis factor-alpha (pg/mL), intercellular adhesion molecule-1 (pg/mL), vascular cell adhesion molecule-1 (pg/mL), high-sensitivity C-reactive protein (pg/mL).
  • Markers of oxydative stress in the blood
    • Time Frame: 1 hour
    • Blood samples for measurements of biomarkers of oxidative stress are collected in the morning the day of the visit. Blood : Glutathione (GSH and GSSG (nmol/mg of proteins)) and Redox potential using the Nernst equation and the values of GSH and GSSG (mV).
  • Markers of oxydative stress in the urine
    • Time Frame: 1 hour
    • Urine 8-prostaglandin F2-alpha (pg/mL).
  • Markers of oxydative stress in the plasma
    • Time Frame: 1 hour
    • Oxidized LDL (U/L)

Secondary Measures

  • CVD risk factors and indicators of (sub)clinical disease: blood pressure
    • Time Frame: 1 hour
    • Blood pressure (mmHg)
  • CVD risk factors and indicators of (sub)clinical disease: Cardiac structure and function by echocardiography- LV hypertrophy #1
    • Time Frame: 30 min
    • Cardiac structure and function by echocardiography. Left ventricle hypertrophy determined by the LV mass (g) indexed to body surface area (BSA in m2) giving a unit of g/m2.
  • CVD risk factors and indicators of (sub)clinical disease: Cardiac structure and function by echocardiography- LV hypertrophy #2
    • Time Frame: 30 min
    • Cardiac structure and function by echocardiography. Left ventricle hypertrophy determined by the interventricular septum thickness (cm).
  • CVD risk factors and indicators of (sub)clinical disease: Cardiac structure and function by echocardiography -LV hypertrophy #3
    • Time Frame: 30 min
    • Cardiac structure and function by echocardiography. Left ventricle hypertrophy determined by LV dysfunction (%) or by endocardial fractional shortening (%)
  • CVD risk factors and indicators of (sub)clinical disease: Arterial structure and function by ultrasound.
    • Time Frame: 1 hour
    • Arterial structure and function (mm) will be measured using a Dopller ultrasound.
  • CVD risk factors and indicators of (sub)clinical disease: Adiposity measures #1
    • Time Frame: 15 min
    • Body mass index in kg/m2, calculating using the weight in kg and the height in m
  • CVD risk factors and indicators of (sub)clinical disease: Adiposity measures #2
    • Time Frame: 30 min
    • Using lean and fat body (g) m
  • CVD risk factors and indicators of (sub)clinical disease: glucose homeostasis
    • Time Frame: 2 hours
    • Plasma fasting glucose (mmol/L) and insulin (mmol/L) and different times after a 75 g of glucose load.
  • CVD risk factors and indicators of (sub)clinical disease: Fasting lipid profile
    • Time Frame: 1 hour
    • Plasma triglycerides (mmol/L), HDL (mmol/L) and LDL (mmol/L).
  • CVD risk factors and indicators of (sub)clinical disease: kidneys functions #1
    • Time Frame: 30 min
    • Urinary protein excretion (albumin/creatinine ratio, mg/mmol), eGFR cystatin C (cystatin C : mg/L) (mL/min/1.73 m2). The formula use the cystatin C values in mg/mL, the standardized serum cystatin min and max, the age (in years) and the sex (female: 0.932, male : 1).
  • CVD risk factors and indicators of (sub)clinical disease: kidneys functions #2
    • Time Frame: 15 min
    • Use of the eGFR cystatin C formula (cystatin C : mg/L) (mL/min/1.73 m2). The formula use the cystatin C values in mg/mL, the standardized serum cystatin min and max, the age (in years) and the sex (female: 0.932, male : 1).
  • CVD risk factors and indicators of (sub)clinical disease: pulmonary functions #1
    • Time Frame: 30 min
    • FEV (%)
  • CVD risk factors and indicators of (sub)clinical disease: pulmonary functions #2
    • Time Frame: 30 min
    • Airflow obstruction (FEV1/FVC ratio, no units).
  • CVD risk factors and indicators of (sub)clinical disease: Questionnaires #1
    • Time Frame: 2 hours
    • Determinants of health. Questionnaires about socio-economics status, family history, personal medical history.
  • CVD risk factors and indicators of (sub)clinical disease: Questionnaires #2
    • Time Frame: 2 hours
    • Determinants of health. Maternal obstetrical and subjects neonatal history.
  • CVD risk factors and indicators of (sub)clinical disease: Questionnaires #3
    • Time Frame: 2 hours
    • Determinants of health. Health-related behaviors
  • CVD risk factors and indicators of (sub)clinical disease: Questionnaires #4
    • Time Frame: 2 hours
    • Determinants of health. Food frequency questionnaire

Participating in This Clinical Trial

Inclusion Criteria

EPT :

  • Birth at GA<29 wks – Age 18-29 years at the time of assessment (age of peak human physiological function) Terms: – Birth at GA ≥37 wks – Born in Quebec, to account for health care access during pregnancy and throughout infancy/childhood – Birth date within 2 years of index case – Age 18-29 years at the time of assessment – Same self-reported race as preterm participant. Exclusion Criteria:

Both groups :

  • Currently pregnant due to X-ray related risks – Severe neurosensory deficit preventing test completion. – In case of twins (or +), if both fulfil inclusion criteria, only one will selected (random) to participate to the study

Gender Eligibility: All

The extremely preterm subjects need to come with a same sex born term subject.

Minimum Age: 18 Years

Maximum Age: 29 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • St. Justine’s Hospital
  • Collaborator
    • Jewish General Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Anne Monique NUYT,MD, MD, Professor of Pediatrics – St. Justine’s Hospital
  • Overall Official(s)
    • Anne Monique Nuyt, MD, Principal Investigator, St. Justine’s Hospital
    • Thuy Mai Luu, MD, Principal Investigator, St. Justine’s Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.